NEOG
Neogen Corporation · Healthcare · Medical - Devices
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2026
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 1 | 0 | 90.75K | $1.06M | n/a | n/a |
| Q2 2026 | 99 | -2 | 145.67M | $1.31B | +8 | −11 |
| Q1 2026 | 105 | +4 | 149.62M | $1.39B | +10 | −7 |
| Q4 2025 | 101 | +1 | 145.41M | $1.02B | +3 | −1 |
| Q3 2025 | 15 | 0 | 86.70M | $495.04M | +1 | −2 |
| Q2 2025 | 13 | +1 | 84.31M | $402.96M | +2 | −1 |
| Q1 2025 | 9 | 0 | 40.38M | $350.08M | +1 | −1 |
| Q4 2024 | 9 | -2 | 40.94M | $497.00M | n/a | −2 |
| Q3 2024 | 10 | 0 | 36.89M | $620.15M | n/a | n/a |
| Q2 2024 | 10 | n/a | 39.27M | $613.84M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Wealth Enhancement Advisory… | 90.75K | +4.1% | $1.06M | 0.0% | ▲ Add | 4 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 307 holders, 232.63M shares, $1.97B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
Officer, Director · CEO · 505 sh @ 11.95 · $6,035
Open-market sales (S)
No open-market insider sales in our coverage window.
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology